Viral Hepatitis Association of Nigeria (VHAN) is a preventive and early detective consultancy medical association charged with the responsibility of advocacy and creation of awareness on Viral and non-viral Hepatitis. Viral Hepatitis Association of Nigeria conduct research worldwide to improve POLICIES, PROGRAMS, and PRODUCTS in the area of Viral and non-Viral Hepatitis.
With over 10 years of operational experience, we have been able to create awareness against viral hepatitis to more than three million Nigerians.
As at today, we are number one ranking as providers of services concerning viral hepatitis and we have been able to achieve with our professionals and affiliations we have made over the time.
Our Mission
We are on the mission to ensure a Hepatitis free nation/Nigeria through the provision of value added strategies for prevention of viral hepatitis infection of those infected and affected. These we do through research, advocacy, encourage government policies, seminars and provision of products for all at risk of the disease and provision of strategic care for those infected.
Our Vision
A Nigeria frees Viral and non-Viral Hepatitis
Strategic Approaches
Researches, survey, advocacy, professional seminars, public lectures, conferences, (National, International and Regional), training workshops, and publications.
Facilitation
Much of the researches, awareness creation, screening, programs and products administration on all our beneficiaries are carried out by our medical professionals and consultants within and outside Nigeria who are members of this organization.
Objectives
Core-Values
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close